Abstract
Rheumatoid arthritis (RA) is a destructive inflammatory arthritis of unknown origin. With the advent of DMARDs and biological agents, the goal of treatment is the induction of remission and prevention of tissue damage in both the elderly and the general RA population. Aging, in particular, can be associated with a decline in the physiologic function of body organs, as well as considerable changes in pharmacodynamics and pharmacokinetics. This makes treatment challenging in elderly RA patients. Thus, a treatment plan must be tailored to meet the severity of the disease and to account for the presence of any comorbidities, especially in the elderly, who may be more frail. Adverse events, such as an increased incidence of infections and malignancy, in some elderly RA patients might be attributed to increased comorbidities with physiologic aging rather than the patient’s chronological age. In particular, this applies to the natural decrement in immunoregulation that occurs in the elderly. In summary, the trea...
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
